HC Wainwright upgrades Alnylam Pharmaceuticals to Buy, setting a $400 price target.
HC Wainwright has rated Alnylam Pharmaceuticals (NASDAQ:ALNY) as a Buy, setting a price target of $400. The company reported Q2 earnings of ($0.13) per share, surpassing estimates of ($0.74), with revenues reaching $659.83 million, up 107% year-over-year. Analysts generally rate it as a Moderate Buy with an average target of $278.59. Notable insider trading includes significant stock sales by CEO Yvonne Greenstreet and other directors.
September 01, 2024
3 Articles